|Bid||1,601.00 x 16300|
|Ask||1,840.00 x 34600|
|Day's Range||1,680.20 - 1,737.50|
|52 Week Range||814.20 - 2,089.00|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2017 - Mar 20, 2017|
|Forward Dividend & Yield||0.19 (1.05%)|
|1y Target Est||24.10|
Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices
Postal company Royal Mail (RMG.L) is set to lose its place in the FTSE 100 (.FTSE), while insurer Hiscox (HSX.L) is likely to join Britain's top stock index in a reshuffle next week, analysts said. Demotion from the blue-chip index would come just as Royal Mail heads into its busiest time of year, as Britons send millions of greeting cards to family and friends in the run-up to Christmas. The possible swap comes after Royal Mail unveiled a broad review of its operations as it battles to cut costs after reporting a 25 percent drop in half-year profit.
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.
Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of Hikma Pharmaceuticals PLC , today announced the appointment of Kristy Ronco as Executive Vice President, Sales and Marketing for its Generics Division.
I am going to run you through how I calculated the intrinsic value of Hikma Pharmaceuticals PLC (LON:HIK) by projecting its future cash flows and then discounting them to today’sRead More...
By Kit Rees and Helen Reid LONDON (Reuters) - Britain's top share index sank on Wednesday as emerging markets stress and a sharp selloff in commodities drove down stocks across Europe, with investors running ...
The Jordanian drugmaker said it sold more injectable opioids in the United States due to a supply shortage, and had a better-than-forecast performance in generics for the first half of the year as its prices proved more resilient than expected. The higher forecast in generics comes as global generic drugmakers with operations in the U.S. cut profit forecasts because of pricing pressure. Novartis said last month that 2018 sales at its generics unit, Sandoz, would fall in the low single-digit percentages, after previously holding out hopes for them to remain steady.
I am going to take a deep dive into Hikma Pharmaceuticals PLC’s (LON:HIK) most recent ownership structure, not a frequent subject of discussion among individual investors. When it comes toRead More...
LAS VEGAS (AP) — A maker of the powerful synthetic opioid fentanyl joined a bid Monday to block the use of its product in what would be the first execution in Nevada in more than 12 years using a three-drug combination never before tried in any state.
London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.
Hikma Pharmaceuticals PLC (the Hikma Group) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), the multinational generic pharmaceutical company, announced today that its US business has begun releasing significant quantities of hydromorphone to US hospital customers to help ease a current shortage of injectable opioids used to treat patients. In response to this shortage, Hikma released more than five million hydromorphone 2ml vials to US hospitals during June, and expects to release another three million vials during July. The current US hospital shortage of injectable opioids used for patient pain management occurred when a significant supplier to the US market temporarily ceased manufacturing.
The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million (407 million pounds) and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals (TEVA.TA), was named Hikma's chief executive officer in February. The company suffered a setback in March for its generic version of GlaxoSmithKline's (GSK.L) blockbuster lung drug Advair, after the U.S. Food and Drug Administration asked Hikma to conduct a further clinical study evaluating the drug, dashing hopes to get it to the market this year.